The i-4-1-Health project is a One Health project on the prevalence and spread of antimicrobial resistance in the human and veterinary domain in the Dutch-Belgian cross-border region. This paper describes the main components of the laboratory protocol that was developed to standardise the microbiological methods used for the detection of intestinal carriage of highly-resistant microorganisms.
INTRODUCTION
The global emergence and spread of antimicrobial resistance pose a critical threat to public health and livestock agriculture. The understanding and control of antimicrobial resistance is a complex global health challenge and asks for One Health approaches at both national and international levels. [1] [2] [3] [4] The i-4-1-Health project aims to address gaps in current knowledge and understanding of the complex routes of dissemination of antibiotic resistance by taking a One Health approach that includes both the human and veterinary domain and targets antibiotic use, infection control and antimicrobial resistance in the Dutch-Belgian cross-border region. Data are collected in hospitals, nursing homes, daycare centres, primary schools, and livestock farms. To the best of our knowledge, this is the first project to study intestinal carriage of a wide range of antimicrobial-resistant microorganisms in the human and veterinary domain in a cross-border setting.
This laboratory protocol was developed by the participating laboratories to standardise the microbiological methods used for the detection of intestinal carriage of highly-resistant microorganisms (HRMO), including extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Gram-negative bacteria (carbaR-GNS), colistin-resistant Enterobacterales (coliR-E), ciprofloxacin-resistant Enterobacterales (ciproR-E) and vancomycin-resistant enterococci (VRE).
METHODS

Study period and setting
The i-4-1-Health study is performed in the Dutch-Belgian border region, comprising eight provinces 
Microbiological methods
Microbiological methods are standardised across the nine participating laboratories (Figure 3 
Data labelling
The labelling system is designed to ensure that data are collected, stored and accessible in a way that permits cross-border and cross-domain analyses. Unique study numbers are generated for each human and veterinary sample included in the study. Each study number contains unique numeric codes for 'country', 'domain', 'institution or farm', 'ward, group or stable', 'survey' and a serial number ( Figure 4 ). The study number used for the collection of microbiological data is identical to that used for the collection of demographic and clinical data. Labels with study numbers are pre-printed to avoid errors of transcription and interpretation with hand-written labels. For each ward or stable, one sheet with all labels for the ward or stable is prepared.
Unique isolate numbers are generated for each antimicrobial-resistant bacterial isolate stored. Each isolate number contains a unique numeric code for 'laboratory' and a serial number (Figure 4 ).
Data storage
Microbiological culture results are recorded in the local laboratory information system. At regular intervals, data are transferred to the central database where the data undergo final cleaning and are prepared for analyses. For the veterinary domain, approval by an animal welfare body is not required. The procedure to collect fresh faecal droppings is considered to cause no discomfort, and animals are neither handled nor sacrificed during the study (EC Directive 2010/63).
All human data are anonymised, i.e. data cannot be directly or indirectly related to their source. Data on institutions and farms are pseudonymised, i.e. identifying information is replaced by a code, and a key file that links this code to the identifying information is kept separate from the research data.
Data sharing
During the study, feedback of resistance data is provided in-between surveys in hospitals and livestock farms. All investigators will have access to the final datasets and bacterial isolate collections to the extent necessary for answering research questions that are included as such in the i-4-1-Health publication plan. The findings will be presented at national and international conferences and submitted to peer-reviewed journals for publication. Publications are anticipated from 2019 and onwards. No earlier than December 31 st , 2020 and no later than December 31 st , 2024, the final datasets and isolate collections will be made available in accordance with the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. 9
DISCUSSION
Strengths
• The i-4-1-Health project takes a One Health approach to address gaps in current knowledge and understanding of the complex routes of dissemination of antibiotic resistance.
• It is the first project to study intestinal carriage of a wide range of antimicrobial-resistant microorganisms in the human and veterinary domain in a cross-border setting using uniform methodology across domains.
• Repeated measurements in hospitals and livestock farms make it possible to study trends over time.
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• The use of pre-enrichment and selective agar plates increases the sensitivity of the methods to detect intestinal carriage of HRMO. 10, 11 Limitations • The human domain includes patients in hospitals, nursing home residents and children in primary school and daycare centres, but not adults in the general population.
• The veterinary domain includes broiler farms and multiplier pig farms, but not non-chicken poultry farms, finishing pig farms and veal farms. (Table 1) .
c. The method used is dependent on local routine laboratory practice (Table 1) .
d. Broth microdilution is used to determine the MIC for colistin in Enterobacterales.
e. The antibiotic gradient strip method is used to determine the MICs for vancomycin and teicoplanin in enterococci.
Faecal, perianal or gastrointestinal stoma swab
Nylon-flocked swab in Cary-Blair medium (FecalSwab ® , Copan Italy)
Non-selective broth enrichment
Tryptic soy broth (TSB, Copan Italy) h. Neo-Sensitabs TM FEP30 contains cefepime 30 ug.
Selective agar plates
ChromID ® ESBL (bioMérieux) ChromID ® CARBA (bioMérieux) ChromID ® OXA-48 (bioMérieux) ChromID ® VRE (bioMérieux) a McC ciprofloxacin (in house) b EMB colistin (in house) b
Microbial identification
